Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Misonix Previews New OsteoSculpt® Ultrasonic Bone Scalpel

November 15, 2010

FARMINGDALE, N.Y., Nov. 15, 2010 /PRNewswire/ — Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its attendance and exhibition at the 20th Congress of the European Association for Cranial-Maxillofacial Surgery (EACMFS), which was held recently in Bruges, Belgium. The EACMFS is widely regarded as the premier educational event for maxillofacial surgery in Europe. Misonix used this venue to introduce its new OsteoSculpt® Ultrasonic Bone Scalpel for use in facial bone surgery.

During the meeting, Dr. Roland Gilles and his colleagues from Hospital CHC Liege in Belgium presented their initial experience with 28 patients in orthognatic surgery, exclusively using the OsteoSculpt for bone cutting. The team described the OsteoSculpt as safe and beneficial for orthognatic and maxillofacial bone surgery with an absence of nerve lesions while reducing blood loss and operative time. Their detailed findings will be published in the proceedings of the Congress late in the year.

The OsteoSculpt was developed with the help of Dr. Gilles and other surgeon innovators. It is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the safety issues often associated with rotary or reciprocating sharps. Another Misonix product, the BoneScalpel(TM) has been successfully used in thousands of bone surgeries for spinal decompression, spinal fusion, and scoliosis on a worldwide basis at many prestigious academic institutions.

“Misonix is excited by the expanded surgical use of our ultrasonic bone cutting technology,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “The clinical benefits for patient and surgeon over traditional means of bone surgery are evident. This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with visionary thought leaders.”

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


    Investor Relations Contact:
    Kevin McGrath/Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.


Source: newswire